-
[show abstract]
[hide abstract]
ABSTRACT: The objective of this study was to evaluate the activity of daptomycin and other agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected from 2001 to 2010, in order to determine changes and to detect resistance trends.
The study included a total of 1,130 MRSA isolates collected as part of a multicenter surveillance program for antibiotic resistance, Estudio de Vigilancia de Resistencia a los Antimicrobianos (VIRA study), from 51 medical centers throughout Spain between 2001 and 2010. Broth microdilution test was performed according to the Clinical Laboratory Standards Institute guidelines.
Daptomycin showed excellent activity and maintained its activity over time; only one MRSA isolate collected in 2001 was nonsusceptible to this agent (MIC=2 mg/L). Based on the MIC90, daptomycin was 2-4 dilutions more active than vancomycin, teicoplanin and linezolid. Daptomycin retained activity against MRSA isolates that were resistant to linezolid, to quinupristin-dalfopristin, or showed intermediate susceptibility to vancomycin.
Our data and those of other studies, coupled with daptomycin's rapid bactericidal activity, suggest that this antimicrobial could be an alternative in the treatment of severe infections caused by multiresistant S. aureus.
Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia 06/2011; 24(2):107-11. · 0.81 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The in vitro activity of doripenem was evaluated against a recent collection of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates (201 ESBL-producing Enterobacteriaceae [153 Escherichia coli and 48 Klebsiella pneumoniae] and 201 P. aeruginosa). Comparator agents included amikacin, tobramycin, ciprofloxacin, cefepime, cefotaxime, ceftazidime piperacillin-tazobactam, imipenem, and meropenem. Both doripenem and meropenem inhibited 100% of the ESBL-producing Enterobacteriaceae at <or=0.5 microg/mL. For these isolates, the MIC(90) of doripenem (0.12 microg/mL) was 4-fold lower than that of imipenem (0.5 microg/mL). Against P. aeruginosa, the MIC(90) of doripenem and meropenem was 2 microg/mL, 4-fold lower than that of imipenem (8 microg/mL). At an MIC of <or=2 microg/mL, doripenem, meropenem, and imipenem inhibited 90.5%, 89.6%, and 82.1% of P. aeruginosa isolates, respectively. Doripenem maintained activity against imipenem-nonsusceptible isolates of P. aeruginosa; at an MIC of <or=4 microg/mL, it inhibited 15 of the 25 isolates with MICs for imipenem of >4 microg/mL. Doripenem is active against ESBL-producing Enterobacteriaceae and P. aeruginosa isolates. Its activity is similar to that of meropenem and slightly better than that of imipenem. The results of this study suggest that doripenem could be an alternative therapeutic agent for infections caused by these organisms.
European Journal of Clinical Microbiology 09/2010; 29(9):1179-81. · 2.86 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The human and material costs of inappropriate antimicrobial therapy are high. This study was designed to search for a rapid, simple and effective antimicrobial susceptibility test capable of identifying the best treatment strategy against microorganisms causing hospital infections showing resistance or reduced susceptibility to the more traditional antibiotics. The tests compared were the E-test, an automated test (Wider) and broth microdilution ( as the reference test), to determine the susceptibility to vancomycin, teicoplanin, linezolid and daptomycin of clinical isolates of methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant coagulase negative Staphylococcus spp. and Enterococccus spp. The E-test and Wider methods showed good agreement with the reference method indicating their reliability for routine susceptibility testing of staphylococci and enterococci against vancomycin, teicoplanin, linezolid and daptomycin. Notwithstanding, when faced with a serious enterococcal infection, the MIC of daptomycin should be more accurately determined using a reference technique such as broth microdilution.
Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia 06/2010; 23(2):87-92. · 0.81 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Introduction. As the number of multidrug-resistant strains of Pseudomonas aeruginosa has risen in the intensive care unit (ICU) of the San Carlos Clinic Hospital, 12 consecutive isolates from different patients were collected to determine the possibility of an epidemic outbreak caused by the spread of a single strain. We determined the antimicrobial susceptibility to the most common agents used in the treatment of infections caused by this bacteria. The results of susceptibility studies suggest that different strains of P. aeruginosa are responsible for the respiratory tract infections in ICU. Methods. The clonal relationship between the isolates using was determined using BOX and ERIC primers by means of repetitive sequence-based polymerase chain reaction (rep-PCR). The in vitro activity of these strains against colistin, rifampicin, doxicycline and azythromycin was studied to determine in which cases the combination of colistin with any of the other three antibiotics was synergistic. Results. Sensitivity studies point out the presence of several strains of P. aeruginosa as the causal agents of respiratory infections produced by this microorganism in the ICU. Combinations of colistin with doxycicline and colistin with azithromycin were synergistic for some isolates in the synergy studies. Discussion. Clonal studies reveal the presence of five different clones among our isolates. Therefore we can conclude that there was no outbreak of P. aeruginosa in the ICU. Synergistic activity of combinations of colistin plus azithromycin, colistin plus doxicycline and colistin plus rifampicin was less than expected and a high percentage of indifferent results was observed.
Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia 10/2008; 21(3):189-93. · 0.81 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: European Union directive 90/128/EEC prescribes a specific migration limit of 0.05 mg/kg for the aliphatic diamine m-xylylenediamine (m-XDA) into food or food simultants, but there is no generally accepted method of analysis available for compliance testing with the given restriction. A method is described for the determination of m-XDA monomer in the following food simulants: distilled water, 3% (w/v) acetic acid, and 15% (v/v) ethanol. The method is appropriate for the quantitative determination of m-XDA at a minimum level of 0.020 mg/kg in these food simulants. Detection limits are in the range of 0.004 to 0.010 mg m-XDA per kilogram food simulant (depending on the type of food simulant). The method should also be applicable to other aqueous food simulants. m-XDA in aqueous simulant test samples is determined by high-performance liquid chromatography with fluorescence detection following derivatization with fluorescamine. Quantitation is relative to external standards. The identity of m-XDA may be confirmed by the presence of a second peak in the chromatograms obtained from samples derivatized with less fluorescamine or by comparison with authentic samples.
Journal of chromatographic science 12/1998; 36(11):554-60. · 0.88 Impact Factor
